The role of microRNAs in skin fibrosis

Olubukola Babalola, Andrew Mamalis, Hadar Lev-Tov, Jared Jagdeo

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Fibrotic skin disorders may be debilitating and impair quality of life. There are few effective treatment options for cutaneous fibrotic diseases. In this review, we discuss our current understanding of the role of microRNAs (miRNAs) in skin fibrosis. miRNAs are a class of small, non-coding RNAs involved in skin fibrosis. These small RNAs range from 18 to 25 nucleotides in length and modify gene expression by binding to target messenger RNA (mRNA), causing degradation of the target mRNA or inhibiting the translation into proteins. We present an overview of the biogenesis, maturation and function of miRNAs. We highlight miRNA's role in key skin fibrotic processes including: transforming growth factor-beta signaling, extracellular matrix deposition, and fibroblast proliferation and differentiation. Some miRNAs are profibrotic and their upregulation favors these processes contributing to fibrosis, while anti-fibrotic miRNAs inhibit these processes and may be reduced in fibrosis. Finally, we describe the diagnostic and therapeutic significance of miRNAs in the management of skin fibrosis. The discovery that miRNAs are detectable in serum, plasma, and other bodily fluids, and are relatively stable, suggests that miRNAs may serve as valuable biomarkers to monitor disease progression and response to treatment. In the treatment of skin fibrosis, anti-fibrotic miRNAs may be upregulated using mimics and viral vectors. Conversely, profibrotic miRNAs may be downregulated by employing anti-miRNAs, sponges, erasers and masks. We believe that miRNA-based therapies hold promise as important treatments and may transform the management of fibrotic skin diseases by physicians.

Original languageEnglish (US)
Pages (from-to)763-776
Number of pages14
JournalArchives of Dermatological Research
Volume305
Issue number9
DOIs
StatePublished - Nov 2013

Fingerprint

MicroRNAs
Fibrosis
Skin
Skin Diseases
Therapeutics
Small Untranslated RNA
Messenger RNA
RNA Stability
Protein Biosynthesis
Porifera
Masks
Transforming Growth Factor beta
Extracellular Matrix
Disease Progression
Up-Regulation
Down-Regulation
Nucleotides
Fibroblasts
Biomarkers
Quality of Life

Keywords

  • Collagen
  • MicroRNA
  • miRNA
  • Skin fibrosis
  • Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

The role of microRNAs in skin fibrosis. / Babalola, Olubukola; Mamalis, Andrew; Lev-Tov, Hadar; Jagdeo, Jared.

In: Archives of Dermatological Research, Vol. 305, No. 9, 11.2013, p. 763-776.

Research output: Contribution to journalArticle

Babalola, Olubukola ; Mamalis, Andrew ; Lev-Tov, Hadar ; Jagdeo, Jared. / The role of microRNAs in skin fibrosis. In: Archives of Dermatological Research. 2013 ; Vol. 305, No. 9. pp. 763-776.
@article{ccd17de230e84796b2c3c52a88e32e02,
title = "The role of microRNAs in skin fibrosis",
abstract = "Fibrotic skin disorders may be debilitating and impair quality of life. There are few effective treatment options for cutaneous fibrotic diseases. In this review, we discuss our current understanding of the role of microRNAs (miRNAs) in skin fibrosis. miRNAs are a class of small, non-coding RNAs involved in skin fibrosis. These small RNAs range from 18 to 25 nucleotides in length and modify gene expression by binding to target messenger RNA (mRNA), causing degradation of the target mRNA or inhibiting the translation into proteins. We present an overview of the biogenesis, maturation and function of miRNAs. We highlight miRNA's role in key skin fibrotic processes including: transforming growth factor-beta signaling, extracellular matrix deposition, and fibroblast proliferation and differentiation. Some miRNAs are profibrotic and their upregulation favors these processes contributing to fibrosis, while anti-fibrotic miRNAs inhibit these processes and may be reduced in fibrosis. Finally, we describe the diagnostic and therapeutic significance of miRNAs in the management of skin fibrosis. The discovery that miRNAs are detectable in serum, plasma, and other bodily fluids, and are relatively stable, suggests that miRNAs may serve as valuable biomarkers to monitor disease progression and response to treatment. In the treatment of skin fibrosis, anti-fibrotic miRNAs may be upregulated using mimics and viral vectors. Conversely, profibrotic miRNAs may be downregulated by employing anti-miRNAs, sponges, erasers and masks. We believe that miRNA-based therapies hold promise as important treatments and may transform the management of fibrotic skin diseases by physicians.",
keywords = "Collagen, MicroRNA, miRNA, Skin fibrosis, Therapeutics",
author = "Olubukola Babalola and Andrew Mamalis and Hadar Lev-Tov and Jared Jagdeo",
year = "2013",
month = "11",
doi = "10.1007/s00403-013-1410-1",
language = "English (US)",
volume = "305",
pages = "763--776",
journal = "Archives of Dermatological Research",
issn = "0340-3696",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - The role of microRNAs in skin fibrosis

AU - Babalola, Olubukola

AU - Mamalis, Andrew

AU - Lev-Tov, Hadar

AU - Jagdeo, Jared

PY - 2013/11

Y1 - 2013/11

N2 - Fibrotic skin disorders may be debilitating and impair quality of life. There are few effective treatment options for cutaneous fibrotic diseases. In this review, we discuss our current understanding of the role of microRNAs (miRNAs) in skin fibrosis. miRNAs are a class of small, non-coding RNAs involved in skin fibrosis. These small RNAs range from 18 to 25 nucleotides in length and modify gene expression by binding to target messenger RNA (mRNA), causing degradation of the target mRNA or inhibiting the translation into proteins. We present an overview of the biogenesis, maturation and function of miRNAs. We highlight miRNA's role in key skin fibrotic processes including: transforming growth factor-beta signaling, extracellular matrix deposition, and fibroblast proliferation and differentiation. Some miRNAs are profibrotic and their upregulation favors these processes contributing to fibrosis, while anti-fibrotic miRNAs inhibit these processes and may be reduced in fibrosis. Finally, we describe the diagnostic and therapeutic significance of miRNAs in the management of skin fibrosis. The discovery that miRNAs are detectable in serum, plasma, and other bodily fluids, and are relatively stable, suggests that miRNAs may serve as valuable biomarkers to monitor disease progression and response to treatment. In the treatment of skin fibrosis, anti-fibrotic miRNAs may be upregulated using mimics and viral vectors. Conversely, profibrotic miRNAs may be downregulated by employing anti-miRNAs, sponges, erasers and masks. We believe that miRNA-based therapies hold promise as important treatments and may transform the management of fibrotic skin diseases by physicians.

AB - Fibrotic skin disorders may be debilitating and impair quality of life. There are few effective treatment options for cutaneous fibrotic diseases. In this review, we discuss our current understanding of the role of microRNAs (miRNAs) in skin fibrosis. miRNAs are a class of small, non-coding RNAs involved in skin fibrosis. These small RNAs range from 18 to 25 nucleotides in length and modify gene expression by binding to target messenger RNA (mRNA), causing degradation of the target mRNA or inhibiting the translation into proteins. We present an overview of the biogenesis, maturation and function of miRNAs. We highlight miRNA's role in key skin fibrotic processes including: transforming growth factor-beta signaling, extracellular matrix deposition, and fibroblast proliferation and differentiation. Some miRNAs are profibrotic and their upregulation favors these processes contributing to fibrosis, while anti-fibrotic miRNAs inhibit these processes and may be reduced in fibrosis. Finally, we describe the diagnostic and therapeutic significance of miRNAs in the management of skin fibrosis. The discovery that miRNAs are detectable in serum, plasma, and other bodily fluids, and are relatively stable, suggests that miRNAs may serve as valuable biomarkers to monitor disease progression and response to treatment. In the treatment of skin fibrosis, anti-fibrotic miRNAs may be upregulated using mimics and viral vectors. Conversely, profibrotic miRNAs may be downregulated by employing anti-miRNAs, sponges, erasers and masks. We believe that miRNA-based therapies hold promise as important treatments and may transform the management of fibrotic skin diseases by physicians.

KW - Collagen

KW - MicroRNA

KW - miRNA

KW - Skin fibrosis

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84886723147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886723147&partnerID=8YFLogxK

U2 - 10.1007/s00403-013-1410-1

DO - 10.1007/s00403-013-1410-1

M3 - Article

C2 - 24022477

AN - SCOPUS:84886723147

VL - 305

SP - 763

EP - 776

JO - Archives of Dermatological Research

JF - Archives of Dermatological Research

SN - 0340-3696

IS - 9

ER -